Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (NYSE:BMY)

seekingalpha.com · 2026-10-30

Bristol-Myers Squibb is downgraded to Hold as its current valuation appears optimistic ahead of looming patent cliffs. Read more on BMY stock here.

TickrTrends take: Bristol-Myers Squibb faces significant patent expiration challenges that could pressure revenue in coming years, a concern that becomes more acute when the stock trades at overvalued levels according to TickrTrends analysis. The company's progress on product development and pipeline initiatives may help offset some revenue headwinds, but investors focused on valuation should monitor whether new launches can adequately replace revenue from drugs losing patent protection. In the Healthcare sector where BMY competes, the combination of looming patent cliffs and current overvaluation suggests that execution on pipeline products will be critical to justify the stock's current price level.

Read the full story at seekingalpha.com →